Radioisotope Production (Iodine-123)

I-123 decays by electron capture and gamma emission with a half-life of 13.2 hours. It is typically produced in cyclotrons by bombarding xenon-124 with protons. The resulting I-123 is then chemically incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of cyclotrons, xenon-124 targets, and radiochemistry facilities. Logistical challenges include the rapid transport and delivery of I-123 radiopharmaceuticals due to their relatively short half-life. Accessibility for developing countries is influenced by the high cost and technical expertise required for production and handling.

I-131 production and application are well-established, with widespread use in nuclear medicine.

I-123 is a radioactive isotope that emits gamma rays, requiring careful handling procedures and physical shielding to minimise radiation exposure.

All radioactive isotopes can be misused, and as such, robust security protocols around chain of custody, inventory management, and physical security are critical.

Due to the absence of nuclear materials, IAEA safeguards are not applicable.